These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6821809)

  • 1. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
    Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
    Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy.
    Balch CM; Smalley RV; Bartolucci AA; Burns D; Presant CA; Durant JR
    Cancer; 1982 Mar; 49(6):1079-84. PubMed ID: 7037155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immunotherapy in the management of patients with malignant melanoma.
    Goodnight JE; Morton DL
    World J Surg; 1979 Jul; 3(3):309-20. PubMed ID: 382645
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant therapy of melanoma.
    Agarwala SS; Kirkwood JM
    Semin Surg Oncol; 1998 Jun; 14(4):302-10. PubMed ID: 9588723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
    Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
    Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
    Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
    Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.